제넥신
Financials
Valuation Metrics
제넥신's Market Cap is ₩975B. At end of 2025 it was ₩2134B. Ranked #1213 of 2,410 in KR market (top 50%), #652 of 1,631 on KOSDAQ (top 40%), #135 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 58%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 97.46B KRW | KR#1,213/2,410 Sec#135/231 |
| Revenue | 4.97B KRW | KR#2,334/2,410 Sec#197/231 |
| Net Income | -32.30B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 331.75B KRW | KR#983/2,410 Sec#61/231 |
| Net Assets | 200.12B KRW | KR#947/2,410 Sec#66/231 |
| Employees | 89 | KR#1,728/2,410 Sec#137/231 |
| Value | ||
| P/B | 0.49x | KR#879/2,410 Sec#43/231 |
| P/S | 19.61x | KR#2,334/2,410 Sec#186/231 |
| FCF Yield | -45.48% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -16.14% | KR#2,037/2,410 Sec#157/231 |
| ROA | -9.74% | KR#2,090/2,410 Sec#157/231 |
| Op. Margin | -798.72% | KR#2,365/2,410 Sec#211/231 |
| Revenue Growth | 229.89% | KR#31/2,410 Sec#9/231 |
| Financial Health | ||
| Debt Ratio | 65.78% | KR#1,158/2,410 Sec#138/231 |
| Total Debt | 114.87B KRW | KR#680/2,410 Sec#41/231 |
| FCF | -44.32B KRW | KR#2,054/2,410 Sec#204/231 |
| Cash | 10.08B KRW | KR#1,690/2,410 Sec#144/231 |
| Current Ratio | 0.27x | KR#2,204/2,410 Sec#215/231 |
| Performance | ||
| 1Y Return | -58.69% | KR#2,107/2,410 Sec#196/231 |
| 1M Return | -22.74% | KR#1,948/2,410 Sec#196/231 |
| From 52W High | -71.43% | KR#2,080/2,410 Sec#175/231 |
| 1Y MDD | -69.86% | KR#1,936/2,410 Sec#163/231 |
| Trading | ||
| Volume | 90,358 shares | KR#580/2,410 Sec#60/231 |
| Trading Value | 193.3M KRW | KR#1,081/2,410 Sec#119/231 |
| Foreign Own. | 3.91% | KR#1,068/2,410 Sec#97/231 |
| Per Share | ||
| EPS | -709 KRW | KR—/2,410 Sec—/231 |
| BPS | 4,394 KRW | KR#1,603/2,410 Sec#115/231 |
Company Info
Established in 1999, the company is a biopharmaceutical enterprise listed on the KOSDAQ market since 2009. Through a 2024 merger with EPD Bio Co., Ltd., it secured the bioPROTAC platform technology EPDeg™. The company is developing various therapeutics, including anticancer immunotherapeutics (GX-I7), utilizing hyFc fusion protein and DNA vaccine manufacturing technologies. It aims for technology transfer through joint development and clinical trials with global pharmaceutical companies to secure future growth engines. Genexine is headquartered in Gangseo-gu, Seoul Metropolitan City.